Abstract 2754: Exploring the interplay between TAM, PD-L1 and immunosuppressive molecules by a novel multiplex immunofluorescence assay in cancer immunotherapy trials
Lisa Adams(Navidea Biopharmaceuticals (United States)), Jennifer Bordeaux(Lineage Cell Therapeutics (United States)), Jehovana O. Bender(Navidea Biopharmaceuticals (United States)), Deepika K. Asnani, Naveen Dakappagari(Navidea Biopharmaceuticals (United States)), Thai H. Tran(Navidea Biopharmaceuticals (United States)), Beiru Chen(Lineage Cell Therapeutics (United States)), Shabnam Tangri(Navidea Biopharmaceuticals (United States))
Cited by 0
Related Papers
Antibody validation
|BioTechniques|2010|601
Linear Motif Atlas for Phosphorylation-Dependent Signaling
|Science Signaling|2008|465
Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti–PD-1 Therapies in Metastatic Melanoma
|Clinical Cancer Research|2018|176
Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement
|JCI Insight|2018|162
In Situ Identification of Putative Cancer Stem Cells by Multiplexing ALDH1, CD44, and Cytokeratin Identifies Breast Cancer Patients with Poor Prognosis
|American Journal Of Pathology|2010|154